Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.
about
Barriers to hepatitis C treatmentHepatitis C virus infection in san francisco’s HIV-infected urban poorFactors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC StudyDiagnosis, management, and treatment of hepatitis C: an updateEducation and counseling in the methadone treatment setting improves knowledge of viral hepatitis.Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services.A trial to reduce hepatitis C seroincidence in drug users.Chronic pain and hepatitis C virus infection in opioid dependent injection drug usersPredictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program.Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users.Barriers to the treatment of hepatitis C. Patient, provider, and system factors.Validity of a self-reported history of a positive tuberculin skin test. A prospective study of drug usersPhysicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.Barriers to accessing care in patients with chronic hepatitis C: the impact of depression.Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C.Burden of blood transmitted infections in substance users admitted for inpatient treatment in Singapore and the associated factors.Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease.Hepatitis infection in the treatment of opioid dependence and abuse.Molecular and contextual markers of hepatitis C virus and drug abuse.Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, ChinaA qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV.Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.HIV among injection drug users in large US metropolitan areas, 1998Estimation of the number of injecting drug users attending an outreach syringe-exchange program and infection with human immunodeficiency virus (HIV) and hepatitis C virus: the AjUDE-Brasil projectThe content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment unitsPsychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenanceEvaluation of an integrated care service facility for people living with hepatitis C in New Zealand.Managing Hepatitis C in Users of Illicit DrugsA comparison of modified directly observed therapy to standard care for chronic hepatitis C.Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance.Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.An overview about hepatitis C: a devastating virus.Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.
P2860
Q27012664-89ED9CFF-5EA4-4280-A7F2-AF539AB64B92Q27473306-FCC1EC73-444B-48DF-987B-A2F0D619EFC8Q27491349-DBE9A9BC-B782-40AA-99FF-0DEC5E83026EQ29619682-45C42655-34D6-4B1C-B0FB-008A903FE951Q30406126-BAF770ED-C82B-4FC9-A802-4D347B0284B4Q33277431-CC544EA6-3044-4A06-A495-8CEA87069757Q33658861-39875641-BAB0-4A02-B7CC-9F94656E66B2Q33872397-AD7C9FFD-7596-4629-A3B8-BA975472EC4AQ34079944-7B8F1893-5AD6-4669-8CE6-7277749249DFQ34088245-82E5BEB9-5ABC-4690-824F-BB5F32045E6BQ34723678-2E269F8C-E557-4EF4-B1B6-373423F7F9CFQ34733731-1C12A0EA-B2F7-4703-80F2-C83575304495Q34789013-D922F0CF-5612-41AA-810A-C34A5A72C702Q34795051-45848030-F12C-4A94-A3F7-AF470A90421AQ34913362-40F23903-7C1C-4051-B015-7FBE0BD706ABQ35087836-F28345BF-EDFE-4545-AF86-B9382069A2AEQ35150028-8C56B256-4556-463B-9F47-B3592CF567D8Q35332315-F161BAFD-8691-4A7B-912D-B15B1BB9413AQ35389163-8620DFB4-C408-44E5-A394-040E62DC79BFQ35660841-D83D9D18-D672-4182-8466-08274CE43B2FQ35773225-FA29B782-2B48-4F6B-B752-252DE3C3D612Q35794148-A9E5AEAF-0697-4E30-8619-D9FCA45FFB54Q36079814-5A2A3107-896B-4211-A594-32FD2376D929Q36260469-FD57042A-28B5-484F-A00A-A79590350DB3Q36272393-BA84096D-4728-4186-8EAB-B22A184D12BAQ36272762-9708945E-233A-42EB-8E67-F3FB1BA01A70Q36272967-7524C852-C9D1-425A-971B-407F4403E40CQ36273036-43D0EB11-5F0C-4D2B-A4D0-8A9F19A9D3DAQ36296243-2F4B0750-5269-49BC-9E0D-5FFFBF4DC501Q36376962-E49698C0-4EAC-4987-923B-7E968F56EEA5Q36421892-E381D8E5-230A-4B0C-86C2-68E0C2FAF525Q36562909-27BFF982-3992-401F-9EBC-2662CA89C4FCQ36700770-9F6A8578-B413-4868-82BD-0CAB03FBF29DQ36948673-5E6FB8E6-C3E9-4A13-AC42-4321B00ACCE1Q36997166-3ED721F4-66E5-4C4F-A8D7-2FBD23955276Q37002923-4084A9A2-9A59-4213-95D0-63000151AC55Q37142229-7665B3E5-FE5B-4866-B798-53DF8D66D592Q37232639-023E1F38-F319-49FC-9486-45825B8A5C34Q37719516-4CC8035D-17D1-4826-B644-1807BD5142F3Q38407675-8BF0357E-8E4D-41B7-B726-CC8A9A088687
P2860
Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hepatitis C disease among inje ...... lingness to receive treatment.
@ast
Hepatitis C disease among inje ...... lingness to receive treatment.
@en
type
label
Hepatitis C disease among inje ...... lingness to receive treatment.
@ast
Hepatitis C disease among inje ...... lingness to receive treatment.
@en
prefLabel
Hepatitis C disease among inje ...... lingness to receive treatment.
@ast
Hepatitis C disease among inje ...... lingness to receive treatment.
@en
P2093
P1476
Hepatitis C disease among inje ...... lingness to receive treatment.
@en
P2093
P304
P356
10.1016/S0376-8716(00)00144-7
P577
2001-02-01T00:00:00Z